Cardiovascular Applications of Hyperpolarized MRI

Current Cardiovascular Imaging Reports

Volumn 4, Issue 2, 2011, Pages 108-115

  Tyler, Damian J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiography; Brute force polarization; Cardiac metabolism; Catheter tracking; Dynamic nuclear polarization; Hyperpolarization; Magnetic resonance imaging; Magnetic resonance spectroscopy; Optical pumping; Parahydrogen induced polarization; Perfusion

Indexed keywords

EID: 84861234142     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-011-9066-8     Document Type: Review

References (50)

1. Mansson, S., E. Johansson, P. Magnusson, et al., 13C imaging-a new diagnostic platform. Eur Radiol, 2006. 16(1): p. 57-67.
2. Bhattacharya, P., B. D. Ross and R. Bunger, Cardiovascular applications of hyperpolarized contrast media and metabolic tracers. Exp Biol Med (Maywood), 2009. 234(12): p. 1395-416.
3. Comment, A., B. van den Brandt, K. Uffmann, et al., Design and performance of a DNP prepolarizer coupled to a rodent MRI scanner. Concepts in Magnetic Resonance Part B-Magnetic Resonance Engineering, 2007. 31B(4): p. 255-269.
4. Fain, S. B., F. R. Korosec, J. H. Holmes, et al., Functional lung imaging using hyperpolarized gas MRI. J Magn Reson Imaging, 2007. 25(5): p. 910-23.
5. Viale, A., F. Reineri, D. Santelia, et al., Hyperpolarized agents for advanced MRI investigations. Q J Nucl Med Mol Imaging, 2009. 53(6): p. 604-17.
6. Ardenkjaer-Larsen, J. H., B. Fridlund, A. Gram, et al., Increase in signal-to-noise ratio of > 10, 000 times in liquid-state NMR. Proc Natl Acad Sci U S A, 2003. 100(18): p. 10158-63.
7. Day, S. E., M. I. Kettunen, F. A. Gallagher, et al., Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med, 2007. 13(11): p. 1382-7.
8. Golman, K., R. I. Zandt, M. Lerche, et al., Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res, 2006. 66(22): p. 10855-60.
9. •• Golman, K., J. S. Petersson, P. Magnusson, et al., Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med, 2008. 59(5): p. 1005-13. This article demonstrates the potential for hyperpolarized MRI to image the regional distribution of different metabolic products in normal and post-ischemic hearts.
10. • Merritt, M. E., C. Harrison, C. Storey, et al., Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci U S A, 2007. 104(50): p. 19773-7. This article demonstrates the utility of hyperpolarized pyruvate in the perfused heart and shows that altered PDH flux can be assessed with high temporal resolution.
11. •• Schroeder, M. A., L. E. Cochlin, L. C. Heather, et al., In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad Sci U S A, 2008. 105(33): p. 12051-6. This is the first manuscript to use hyperpolarized pyruvate to assess the in vivo rat heart and to demonstrate the alterations to in vivo PDH flux caused by overnight fasting and type 1 diabetes.
12. • Golman, K. and J. S. Petersson, Metabolic imaging and other applications of hyperpolarized 13C1. Acad Radiol, 2006. 13(8): p. 932-42. This is an excellent review of the preliminary work exploring the potential applications of hyperpolarized MRI.
13. Ross, B. D., P. Bhattacharya, S. Wagner, et al., Hyperpolarized MR imaging: neurologic applications of hyperpolarized metabolism. AJNR Am J Neuroradiol, 2010. 31(1): p. 24-33.
14. Golman, K., J. H. Ardenkjaer-Larsen, J. S. Petersson, et al., Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A, 2003. 100(18): p. 10435-9.
15. Golman, K., O. Axelsson, H. Johannesson, et al., Parahydrogen-induced polarization in imaging: subsecond (13)C angiography. Magn Reson Med, 2001. 46(1): p. 1-5.
16. Svensson, J., S. Mansson, E. Johansson, et al., Hyperpolarized 13C MR angiography using trueFISP. Magn Reson Med, 2003. 50(2): p. 256-62.
17. Olsson, L. E., C. M. Chai, O. Axelsson, et al., MR coronary angiography in pigs with intraarterial injections of a hyperpolarized 13C substance. Magn Reson Med, 2006. 55(4): p. 731-7.
18. Ishii, M., K. Emami, S. Kadlecek, et al., Hyperpolarized 13C MRI of the pulmonary vasculature and parenchyma. Magn Reson Med, 2007. 57(3): p. 459-63.
19. Schwitter, J., Myocardial perfusion imaging by cardiac magnetic resonance. J Nucl Cardiol, 2006. 13(6): p. 841-54.
20. Johansson, E., L. E. Olsson, S. Mansson, et al., Perfusion assessment with bolus differentiation: a technique applicable to hyperpolarized tracers. Magn Reson Med, 2004. 52(5): p. 1043-51.
21. Johansson, E., S. Mansson, R. Wirestam, et al., Cerebral perfusion assessment by bolus tracking using hyperpolarized 13C. Magn Reson Med, 2004. 51(3): p. 464-72.
22. Magnusson, P., E. Johansson, S. Mansson, et al., Passive catheter tracking during interventional MRI using hyperpolarized 13C. Magn Reson Med, 2007. 57(6): p. 1140-7.
23. Horowitz, J. D. and J. A. Kennedy, Time to address the cardiac metabolic "triple whammy" ischemic heart failure in diabetic patients. J Am Coll Cardiol, 2006. 48(11): p. 2232-4.
24. Neubauer, S., The failing heart-an engine out of fuel. N Engl J Med, 2007. 356(11): p. 1140-51.
25. Stanley, W. C., F. A. Recchia and G. D. Lopaschuk, Myocardial substrate metabolism in the normal and failing heart. Physiol Rev, 2005. 85(3): p. 1093-129.
26. Bailey, I. A., D. G. Gadian, P. M. Matthews, et al., Studies of metabolism in the isolated, perfused rat heart using 13C NMR. FEBS Lett, 1981. 123(2): p. 315-8.
27. Lloyd, S., C. Brocks and J. C. Chatham, Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol, 2003. 285(1): p. H163-72.
28. Sherry, A. D., C. R. Malloy, P. Zhao, et al., Alterations in substrate utilization in the reperfused myocardium: a direct analysis by 13C NMR. Biochemistry, 1992. 31(20): p. 4833-7.
29. Chatham, J. C. and A. M. Seymour, Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc Res, 2002. 55(1): p. 104-12.
30. Malloy, C. R., A. D. Sherry and F. M. Jeffrey, Carbon flux through citric acid cycle pathways in perfused heart by 13C NMR spectroscopy. FEBS Lett, 1987. 212(1): p. 58-62.
31. Ziegler, A., C. E. Zaugg, P. T. Buser, et al., Non-invasive measurements of myocardial carbon metabolism using in vivo 13C NMR spectroscopy. NMR Biomed, 2002. 15(3): p. 222-34.
32. Malloy, C. R., J. R. Thompson, F. M. Jeffrey, et al., Contribution of exogenous substrates to acetyl coenzyme A: measurement by 13C NMR under non-steady-state conditions. Biochemistry, 1990. 29(29): p. 6756-61.
33. Kettunen, M. I., D. E. Hu, T. H. Witney, et al., Magnetization transfer measurements of exchange between hyperpolarized [1-13C]pyruvate and [1-13C]lactate in a murine lymphoma. Magn Reson Med, 2010. 63(4): p. 872-80.
34. Randle, P. J., Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev, 1998. 14(4): p. 263-83.
35. Tyler, D. J., M. A. Schroeder, L. E. Cochlin, et al., Application of hyperpolarized magnetic resonance in the study of cardiac metabolism. Applied Magnetic Resonance, 2008. 34(3-4): p. 523-531.
36. Atherton, H. J., M. A. Schroeder, M. S. Dodd, et al., Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised (13)C MRS. NMR Biomed, 2010.
37. Merritt, M. E., C. Harrison, C. Storey, et al., Inhibition of carbohydrate oxidation during the first minute of reperfusion after brief ischemia: NMR detection of hyperpolarized 13CO2 and H13CO3. Magn Reson Med, 2008. 60(5): p. 1029-36.
38. 13C]pyruvate for the assessment of real-time flux through the TCA cycle and the alterations to this flux that are seen following global ischemia in the perfused heart.
39. 13C]pyruvate for the assessment of intracellular pH in the heart with high temporal resolution.
40. Moreno, K. X., S. M. Sabelhaus, M. E. Merritt, et al., Competition of pyruvate with physiological substrates for oxidation by the heart: implications for studies with hyperpolarized [1-13C]pyruvate. Am J Physiol Heart Circ Physiol, 2010. 298(5): p. H1556-64.
41. Schroeder, M. A., H. J. Atherton, L. E. Cochlin, et al., The effect of hyperpolarized tracer concentration on myocardial uptake and metabolism. Magn Reson Med, 2009. 61(5): p. 1007-14.
42. •• Lau, A. Z., A. P. Chen, N. R. Ghugre, et al., Rapid multislice imaging of hyperpolarized (13)C pyruvate and bicarbonate in the heart. Magn Reson Med, 2010. A new acquisition scheme is presented which allows for rapid, cardiac-gated acquisition of metabolic images with high spatial and temporal resolution.
43. Comment, A., J. Rentsch, F. Kurdzesau, et al., Producing over 100 ml of highly concentrated hyperpolarized solution by means of dissolution DNP. J Magn Reson, 2008. 194(1): p. 152-5.
44. Jannin, S., A. Comment, F. Kurdzesau, et al., A 140 GHz prepolarizer for dissolution dynamic nuclear polarization. J Chem Phys, 2008. 128(24): p. 241102.
45. Johannesson, H., S. Macholl and J. H. Ardenkjaer-Larsen, Dynamic Nuclear Polarization of [1-13C]pyruvic acid at 4. 6 tesla. J Magn Reson, 2009. 197(2): p. 167-75.
46. Cunningham, C. H., A. P. Chen, M. J. Albers, et al., Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. J Magn Reson, 2007. 187(2): p. 357-62.
47. Cunningham, C. H., A. P. Chen, M. Lustig, et al., Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson, 2008. 193(1): p. 139-46.
48. Gallagher, F. A., M. I. Kettunen, S. E. Day, et al., Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature, 2008. 453(7197): p. 940-3.
49. Gallagher, F. A., M. I. Kettunen, S. E. Day, et al., 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med, 2008. 60(2): p. 253-7.
50. Gallagher, F. A., M. I. Kettunen, D. E. Hu, et al., Production of hyperpolarized [1, 4-13C2]malate from [1, 4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci U S A, 2009. 106(47): p. 19801-6.